[Perspectives in the treatment of non-small cell lung cancer stage III with radiotherapy and concomitant low-dosage chemotherapy].
Patients with a non-small cell lung cancer stage III should preferably be treated with a combination of concomitant radiotherapy and platinum-containing chemotherapy. Concomitant chemoradiation results in improved survival compared to sequential chemoradiation, although this type oftreatment is associated with higher oesophagus toxicity. With concomitant chemoradiation the chemotherapy can be added in several ways to high-dosage radiotherapy, for example in the form of 2 courses of high dose, platinum-containing polychemotherapy once every 3 weeks. Concomitant chemoradiation with just a daily low dose of cisplatin is a good alternative. In view of its low risk of haematological and renal toxicity and ototoxicity and smaller cardiac load this is the therapy of choice and is also highly suitable for elderly patients with comorbidity.
Uitterhoeve
A L J
AL
Academisch Medisch Centrum/Universiteit van Amsterdam, Afd. Radiotherapie, Postbus 22.660, 1100 DD Amsterdam. a.l.uitterhoeve@amc.uva.nl
Belderbos
J S A
JS
van Zandwijk
N
N
Koning
C C E
CC
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D009367:Neoplasm Staging; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome